A Systematic Review and Meta-Analysis on Catastrophic Cost incurred by Tuberculosis Patients and their Households

Ramy Mohamed Ghazy; Haider M. El Saeh; Shaimaa Abdulaziz; Esraa Abdellatif Hammouda; Amira Elzorkany; Heba Kheder; Nardine Zarif; Ehab Elrewany; Samar Abd ElHafeez

doi:10.1101/2021.02.27.21252453

Abstract

Background As one of the World Health Organization (WHO) End Tuberculosis (TB) Strategy is to reduce the proportion of TB affected families that face catastrophic costs to 0% by 2020. This systematic review and meta-analysis aimed to estimate the pooled proportion of TB affected households who face catastrophic cost.

Method A search of the online database through September 2020 was performed. A total of 5114 articles were found, of which 29 articles got included in quantitative synthesis. Catastrophic cost is defined if total cost related to TB exceeded 20% of annual pre-TB household income. R software was used to estimate the pooled proportion at 95% confidence intervals (CIs) using the fixed/random-effect models.

Result The proportion of patients faced catastrophic cost was 43% (95% CI 34-52, I² = 99%); 32% (95% CI 29 – 35, I² = 70%) among drug sensitive, and 80% (95% CI 74-85, I² = 54%) among drug resistant, and 81% (95%CI 78-84%, I² = 0%) among HIV patients. Regarding active versus passive case finding the pooled proportion of catastrophic cost was 12% (95% CI 9-16, I² = 95%) versus 42% (95% CI 35-50, I² = 94%). The pooled proportion of direct cost to the total cost was 45% (95% CI 39-51, I² = 91%). The pooled proportion of patients facing catastrophic health expenditure (CHE) at cut of point of 10% of their yearly income was 45% (95% CI 35-56, I² = 93%) while at 40% of their capacity to pay was 63% (95% CI 40-80, I² = 96%).

Conclusion Despite the ongoing efforts, there is a significant proportion of patients facing catastrophic cost, which represent a main obstacle against TB control.

PROSPERO registration CRD42020221283

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This research was partially funded by WHO-TDR (SGS 20-28)

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

Email: ramy_ghazy{at}alexu.edu.eg, Email: ehabelrewany{at}alexu.edu.eg, Email: h.elsaeh{at}uot.edu.ly, E.mail: mri.shaimaa.m.informatics18{at}alexu.edu.eg, Email: Hiph.eabdellatif{at}alexu.edu.eg, E.mail: hiph.amiraelzorkany{at}alexu.edu.eg, E.mail: Nardine_zarif{at}yahoo.com, E.mail: heba_khidr{at}yahoo.com, Email: samarabdelhafeez.epid{at}gmail.com

Data Availability

all data are available.

The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.